Company Overview and News
The U.S. auto industry is now encountering tariff woes. According to the Alliance of Automobile Manufacturers, if 25% tariff is imposed on imported cars and parts, it would escalate the price of U.S. vehicles by $83 billion annually and result in job losses. The auto industry has organized a full-scale campaign to oppose the tariffs. In another development, the week witnessed Ford Motor Company (F - Free Report) agreeing to pay $299.
WBC TM TYT SAH HOG TOYOF CMI CMQMY 7203 500570 AAP TATAMOTORS TTM
Thousands of shoppers in search of heavily discounted items will flock to Amazon on Prime Day, which kicks off July 16 at 3 p.m. ET. This year's event will be the longest ever, with deals running for 36 hours.
In the past week, electric vehicle (EV) manufacturer Tesla, Inc. (TSLA - Free Report) raised prices of Model X and Model S vehicles by 20% in China. In fact, Tesla is the first automaker to increase prices in the world’s largest automotive market. Moreover, the company inked a deal to build its first factory outside the United States. With this factory in Shanghai, Tesla will be the first wholly-owned foreign automaker in China.
VLKAF GM.WS.A GM.WS.B ADI GM.WS.C PCAR GM HOG GM.WSB AAP VLKAY
BEIJING, July 12 — China accused the United States of bullying and warned it would hit back after the Trump administration raised the stakes in their trade dispute, threatening 10 per cent tariffs on US$200 billion of Chinese goods in a move that rattled global markets.
W AZO AAP MSCI
Asian markets dipped as US President Donald Trump raised the pressure on Beijing in a trade war over its intellectual property practices by publishing a list of an additional $US200 billion worth of Chinese goods he plans to hit with a 10% tariff.
W AZO AAP
BEIJING/WASHINGTON: China accused the United States of bullying and warned it would hit back after the Trump administration raised the stakes in their trade dispute, threatening 10 percent tariffs on US$200 billion of Chinese goods and rattling global markets.
W AZO AAP MSCI
BEIJING/WASHINGTON (Reuters) - China accused the United States of bullying and warned it would hit back after the Trump administration raised the stakes in their trade dispute, threatening 10 percent tariffs on $200 billion of Chinese goods and rattling global markets.
W AZO AAP MSCI
The week saw the release of the auto sales report for the month of June. U.S. auto sales jumped in the month, defying the odds of rising interest rates, higher gas prices and large supply of used vehicles. While the first half of the year saw auto sales rise 1.8%, sales in June increased 5% compared with a year ago. Strong consumer confidence and low level of unemployment boosted auto sales. There is however the lurking fear of this joyride being derailed due to President Trump’s proposed tariffs.
DTK HOG JMPLF CMI VLKAF GM.WS.A GM.WS.B ALV GM.WS.C JMPLY GM GM.WSB AAP VLKAY
Harley-Davidson, Inc. (HOG - Free Report) recently announced that it will shift some of its production out of the United States to avoid EU (European Union) tariffs. The automaker’s decision came after Trump’s announcement of imposing tariffs on steel and aluminum, imported from the EU. In retaliation, the EU levied tariffs on U.S. goods, including motorcycles. Understandably, this tariff war has raised concerns among automakers.
VLKAF TM 7203 TYT HOG DDAIF TOYOF AAP BIDU VLKAY
U.S. customers have recently shown a distinct shift in the preference for trucks and sports utility vehicles (SUVs), shunning the traditional sedans. Automakers have already started to reorient their programs and strategies in response to the new situation, where the demand for conventional compact and midsize cars has declined while increased for SUVs and pickup trucks. The recent decision of General Motors Company (GM - Free Report) to abandon three Cadillac sedans and replacing them with two new ones over the next three and a half years vindicates this trend.
HINOF HYUO HOG WGO HYUD VLKAF HINOY MGA GM.WS.A 7205 GM.WS.B MG GM.WS.C GM HYUP GM.WSB AAP VLKAY
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Silicon Investor Message Boards
This table lists all message boards related to AAP / Advance Auto Parts, Inc. on message board site Silicon Investor.
as of ET